Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?

Arthritis Care and Research

Volumn 57, Issue 5, 2007, Pages 748-755

  Rahme, Elham ^a   Barkun, Alan N ^a   Toubouti, Youssef ^a   Scalera, Alissa ^b   Rochon, Sophie ^b   Lelorier, Jacques ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b PFIZER INC   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

COX 2 inhibitors; Gastrointestinal bleeding; NSAIDs; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CELECOXIB; CORTICOSTEROID; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; PROTON PUMPS; PYRAZOLES; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONAMIDES;

EID: 34250680899     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22764     Document Type: Article

References (24)

1. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-40.
2. American College of Rheumatology Committee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328-46.
4. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
5. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, et al, and the Canadian NSAID Consensus Participants. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. CMAJ 1996;155:77-88.
6. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
7. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al, for the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
8. Hawkey CJ, for the Omeprazole NSAID Steering Committee. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Am J Med 1998;104: 67S-74S.
9. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al, for the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
10. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
11. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
12. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
13. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004;127:1038-43.
14. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002;46:3046-54.
15. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24.
16. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48:999-1009.
17. Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rheumatology (Oxford) 2007;46:265-72.
18. Ake CF, Carpenter AL. Survival analysis with PHREG: using MI and MIANALYZE to accommodate missing data: proceedings of the 10th Annual Western Users of SAS Software, Inc. Users Group Conference. Cary (NC): SAS Institute Inc.; 2002.
19. Fleming T, Harrington D. Counting process and survival analysis. New York: Wiley; 1991.
20. Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognosis covariates. J Am Stat Assoc 2000;95:573-85.
21. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343: 1520-8.
22. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published erratum appears in N Engl J Med 2006;355:221]. N Engl J Med 2005;352:1092-102.
23. MacDonald TM, Pettitt D, Lee FH, Schwartz JS. Channeling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology (Oxford) 2003;42 Suppl 3:iii3-10.
24. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.